Scientists at Philips have developed new biosensor technology using nanoparticles - with the potential to expand the rapid diagnosis sector of the in vitro diagnostics market.
'There is already a trend away from centralized treatment and testing, which focuses primarily on acute and late interventions, to one which delivers care in a more patient-friendly way. It is predicted that within 10 years, some complex IVD tests will be taken out of the laboratory.’ Marcel van Kasteel, General Manager Handheld Diagnostics
‘POC platforms of the future need to offer a wide menu with precision and accuracy’ Chris Price, visiting professor, Clinical Biochemistry, University of Oxford
